James Collins - Awakn Life Chief Officer
| AWKNF Stock | USD 0.09 0.01 8.01% |
Insider
James Collins is Chief Officer of Awakn Life Sciences
| Web | https://awaknlifesciences.com |
James Collins Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Collins against Awakn Life otc stock is an integral part of due diligence when investing in Awakn Life. James Collins insider activity provides valuable insight into whether Awakn Life is net buyers or sellers over its current business cycle. Note, Awakn Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Awakn Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Collins over three months ago Acquisition by James Collins of 62500 shares of Senti Biosciences at 0.31 subject to Rule 16b-3 |
Awakn Life Management Efficiency
The company has return on total asset (ROA) of (0.8162) % which means that it has lost $0.8162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.84) %, meaning that it generated substantial loss on money invested by shareholders. Awakn Life's management efficiency ratios could be used to measure how well Awakn Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| James Goding | Opthea | N/A | |
| Rutledge EllisBehnke | Arch Therapeutics | N/A | |
| Ian Leitch | Opthea | 61 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Matthew MBA | Iteos Therapeutics | 51 | |
| Valerie Cros | Cellectis SA | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Joanne MD | Iteos Therapeutics | 52 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Annie Lee | Opthea | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| CPA CPA | Opthea | 63 | |
| Michael Gerometta | Opthea | 59 | |
| Ana Stegic | Antibe Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| MSc MSc | Cellectis SA | 54 | |
| Matthew Gall | Iteos Therapeutics | 47 | |
| Yvonne McGrath | Iteos Therapeutics | 50 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
Management Performance
| Return On Equity | -2.84 | |||
| Return On Asset | -0.82 |
Awakn Life Sciences Leadership Team
Elected by the shareholders, the Awakn Life's board of directors comprises two types of representatives: Awakn Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Awakn. The board's role is to monitor Awakn Life's management team and ensure that shareholders' interests are well served. Awakn Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Awakn Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Scorsis, Cofounder Chairman | ||
| Gordo Whittaker, Chief Officer | ||
| Shaun McNulty, Chief Board | ||
| Pr Morgan, Head Board | ||
| DM FMedSci, Chair Officer | ||
| James Collins, Chief Officer | ||
| MD FACEP, Regional AS | ||
| MBBS BSc, Head CoFounder | ||
| Anthony Tennyson, President, Cofounder |
Awakn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Awakn Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.84 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (8.79) % | |||
| Current Valuation | 6.58 M | |||
| Shares Outstanding | 32.48 M | |||
| Shares Owned By Insiders | 9.92 % | |||
| Shares Owned By Institutions | 8.34 % | |||
| Price To Book | 4.19 X | |||
| Price To Sales | 7.96 X | |||
| Revenue | 236.04 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Awakn OTC Stock
Awakn Life financial ratios help investors to determine whether Awakn OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Awakn with respect to the benefits of owning Awakn Life security.